Joint Clinical Trials Office
NRG-GI011: A PHASE III RANDOMIZED TRIAL OF DOSE ESCALATED RADIATION IN LOCALLY ADVANCED PANCREAS CANCER (LAPC) PATIENTS (LAP100)
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 5, 2026
Communicating Options for Advanced Breast Cancer Support and Treatment (COAST)
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 16, 2026
ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 6, 2026
A Phase 2 Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 14, 2026
Expanded Access Program (EAP) for Obecabtagene Autoleucel (obe-cel) Out-of-specification (OOS) in Adult Patients with Acute Lymphoblastic Leukemia
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 14, 2026
Repository of Novel Analytes Leading to Autoimmune, Inflammatory, and Diabetic Nephropathies (RENAL AID)
Study Status:
Open to Enrollment
Primary Investigator:
Alan Perlman, M.D.
Date: March 15, 2016
(CLONEVO): Cell cycLe inhbitiON to target the EVolution of urOthelial cancer
Study Status:
Open to Enrollment
Primary Investigator:
Bishoy Faltas, M.D.
Date: June 8, 2018
Autosomal Dominant Polycystic Kidney Disease Data Repository
Study Status:
Open to Enrollment
Primary Investigator:
Blumenfeld, Jon M.D.
Date: April 28, 2016
Fecal Microbiota Transplantation National Registry
Study Status:
Open to Enrollment
Primary Investigator:
Carl V. Crawford, Jr., MD
Date: August 24, 2018
A Gene-Transfer, Open-Label, Dose-Escalation Study of SPK-8011 [Recombinant Adeno-Associated Viral Vector with B-Domain Deleted Human Factor VIII Gene] in Individuals with Hemophilia A
Study Status:
Open to Enrollment
Primary Investigator:
Catherine McGuinn
Date: November 2, 2018